Mapp Biopharmaceutical

Overview

• Industrypharmaceutical industry¹
• HeadquartersSan Diego¹
• Websitemappbio.com

See how the biggest companies compare on our leaderboards

Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley. Mapp Biopharmaceutical is based in San Diego, California.²

Products and brands

• biopharmaceutical

Listed on Wikidata.¹

Timeline

1. 2003Founded Founded¹

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Federal awards

Obligated amounts from USAspending.gov⁴, by calendar year, 2008–2026, for its registration. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest grants

1. Jul 23, 2009$9.9M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁵ To MAPP BIOPHARMACEUTICAL, INC. Award U01AI082276
2. Jun 8, 2012$5.9M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁶ To MAPP BIOPHARMACEUTICAL, INC. Award R01AI098774
3. Apr 21, 2014$5.4M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁷ To MAPP BIOPHARMACEUTICAL, INC. Award R01AI111391
4. Apr 1, 2009$3.0M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁸ To MAPP BIOPHARMACEUTICAL, INC. Award R44AI082744
5. Apr 1, 2009$3.0M from National Institutes of Health: Allergy And Infectious Diseases Research; Allergy, Immunology And Transplantation Research⁹ To MAPP BIOPHARMACEUTICAL, INC. Award SB1AI082744
6. Sep 15, 2007$3.0M from National Institutes of Health: Allergy, Immunology And Transplantation Research¹⁰ To MAPP BIOPHARMACEUTICAL, INC. Award R44AI072915
7. May 1, 2005$2.8M from National Institutes of Health: Allergy, Immunology And Transplantation Research¹¹ To MAPP BIOPHARMACEUTICAL, INC. Award U01AI061270
8. Mar 15, 2005$2.8M from National Institutes of Health: Aging Research¹² To MAPP BIOPHARMACEUTICAL, INC. Award R44AG025641

Largest contracts

1. Sep 30, 2022$220.9M from Office of Assistant Secretary for Preparedness and Response: Procurement of therapeutics for ebola, sudan and marburg viruses¹³ To MAPP BIOPHARMACEUTICAL, INC. Award 75A50122C00061
2. Sep 28, 2022$155.2M from Office of Assistant Secretary for Preparedness and Response: This cost-plus-fixed-fee contract with mapp biopharmaceutical, inc. (mapp or contractor) is for the development of mapp?s therapeutic interv¹⁴ To MAPP BIOPHARMACEUTICAL, INC. Award 75A50122C00076
3. Sep 30, 2017$65.8M from Office of Assistant Secretary for Preparedness and Response: Igf::ot::igf¹⁵ To MAPP BIOPHARMACEUTICAL, INC. Award HHSO100201700017C
4. Sep 25, 2018$56.7M from Office of Assistant Secretary for Preparedness and Response: Igf::ot::igf¹⁶ To MAPP BIOPHARMACEUTICAL, INC. Award 75A50118C00024
5. Sep 2, 2014$52.4M from Office of Assistant Secretary for Preparedness and Response: Igf::cl::igf for other functions advanced development of zmapp, an ebola virus candidate medical countermeasure¹⁷ To MAPP BIOPHARMACEUTICAL, INC. Award HHSO100201400009C

Links

• Websitemappbio.com¹
• WikipediaMapp Biopharmaceutical
• WikidataQ17578037